ScinoPharm Taiwan, Ltd. Begins New Era as a Publicly Traded Company
ScinoPharm Taiwan, Ltd. (TWSE1789) a leading global supplier of active pharmaceutical ingredients (APIs), announced that it will begin trading its shares today on the Taiwan Stock Exchange Board. The IPO price of ScinoPharm Taiwan is NTD46 per share; with its outstanding shares of 631 million at IPO, this translates into a market capitalization of NTD29 billion, which tops all participants in the biotech and pharmaceutical sector currently in Taiwan.
President and CEO Dr. Jo Shen of ScinoPharm Taiwan commented that ScinoPharm Taiwan has assembled a complete team of R&D experts specialized in the development of advanced manufacturing processes. Meanwhile, the company is collaborating with both domestic and foreign R&D institutions in making technological improvements that will further enhance its overall R&D efficiency and capabilities. Currently, the company employs more than 150 R&D personnel, most of whom with PhD and Master degrees; the competence of the R&D team provides assurance to the company’s global competitiveness.
President Ming-Chien Cheng of Fubon Securities, the lead underwriter for ScinoPharm’s IPO, commented that ScinoPharm, as Taiwan’s largest API manufacturer, has attracted the attention of many local and foreign investors since its listing on the Emerging Stock Market last year.
ScinoPharm Taiwan’s founding shareholders include the Uni-President Group, the National Development Fund, Taiwan Sugar Corporation, and Mega Bank. ScinoPharm Taiwan’s listing is an example of the Taiwan government’s success in providing the nurturing environment enabling its biotech and pharmaceutical industries to establish their globally-competitive positions. Over 50% of the company’s shares are held by the Uni-President Group, while the National Development Fund and Taiwan Sugar Corporation hold another 18% and other corporate investors hold nearly 10%.
ScinoPharm Taiwan, Ltd. contributes to 65% of the API exported from Taiwan, and is now a leading global producer of APIs for injectable anti-cancer treatments. With over 270 global pharmaceutical customers, the company has accumulated a total of 553 drug master files (DMFs), the highest in Taiwan.
ScinoPharm Taiwan, Ltd. recently expanded its facility in Taiwan including adding a peptide plant. In addition, two large production lines are currently under construction. Meanwhile the first phase of a brand new world-class facility in Changshu, Jiangsu, China will be completed in the fourth quarter of 2011, which includes a full scale R&D center, large production capacities of key intermediates as well as two small to medium GMP API lines. It is expected that by the end of the 2012, the second phase of the construction, mainly for the large GMP API capacities, will be completed.
About ScinoPharm Taiwan
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. For more information, please visit the Company's website at http://www.scinopharm.com.
Contact:
Sabrian Wu
Tel: +886-6-508-2869
Mobile: +886-920-056-385
Email: sabrina.wu@scinopharm.com.tw